These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26309031)

  • 1. Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit.
    Phuong H; Choi BY; Chong CR; Raman B; Horowitz JD
    Ther Drug Monit; 2016 Feb; 38(1):73-8. PubMed ID: 26309031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perhexiline.
    Ashrafian H; Horowitz JD; Frenneaux MP
    Cardiovasc Drug Rev; 2007; 25(1):76-97. PubMed ID: 17445089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of perhexiline on myocardial deformation in patients with ischaemic left ventricular dysfunction.
    Bansal M; Chan J; Leano R; Pillans P; Horowitz J; Marwick TH
    Int J Cardiol; 2010 Mar; 139(2):107-12. PubMed ID: 19840889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.
    Lee L; Campbell R; Scheuermann-Freestone M; Taylor R; Gunaruwan P; Williams L; Ashrafian H; Horowitz J; Fraser AG; Clarke K; Frenneaux M
    Circulation; 2005 Nov; 112(21):3280-8. PubMed ID: 16301359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of aging, renal dysfunction, left ventricular systolic impairment, and weight on steady state pharmacokinetics of perhexiline.
    Ling LH; Chik W; Averbuj P; Pati PK; Sverdlov AL; Ngo DT; Morris RG; Sallustio BC; Horowitz JD
    Ther Drug Monit; 2011 Apr; 33(2):251-6. PubMed ID: 21383654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereoselective handling of perhexiline: implications regarding accumulation within the human myocardium.
    Chong CR; Drury NE; Licari G; Frenneaux MP; Horowitz JD; Pagano D; Sallustio BC
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1485-91. PubMed ID: 26376650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.
    Sallustio BC; Westley IS; Morris RG
    Br J Clin Pharmacol; 2002 Aug; 54(2):107-14. PubMed ID: 12207628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perhexiline maleate treatment for severe angina pectoris--correlations with pharmacokinetics.
    Horowitz JD; Sia ST; Macdonald PS; Goble AJ; Louis WJ
    Int J Cardiol; 1986 Nov; 13(2):219-29. PubMed ID: 3793279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of terbinafine (anti-fungal agent) with perhexiline: a case report.
    Sheikh AR; Westley I; Sallustio B; Horowitz JD; Beltrame JF
    Heart Lung Circ; 2014 Jun; 23(6):e149-51. PubMed ID: 24373912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis.
    Unger SA; Robinson MA; Horowitz JD
    Aust N Z J Med; 1997 Feb; 27(1):24-8. PubMed ID: 9079249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perhexiline--stable plasma concentrations with formulation change.
    Siebert WJ; Gabb GM; Wing LM
    Aust N Z J Med; 1996 Oct; 26(5):707-8. PubMed ID: 8958370
    [No Abstract]   [Full Text] [Related]  

  • 12. Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy.
    Stewart S; Voss DW; Northey DL; Horowitz JD
    Ther Drug Monit; 1996 Dec; 18(6):635-9. PubMed ID: 8946658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a regimen for rapid initiation of perhexiline therapy in acute coronary syndromes.
    Philpott A; Chandy S; Morris R; Horowitz JD
    Intern Med J; 2004 Jun; 34(6):361-3. PubMed ID: 15228400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between plasma, atrial and ventricular perhexiline concentrations in humans: insights into factors affecting myocardial uptake.
    Drury NE; Licari G; Chong CR; Howell NJ; Frenneaux MP; Horowitz JD; Pagano D; Sallustio BC
    Br J Clin Pharmacol; 2014 May; 77(5):789-95. PubMed ID: 24117487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady state.
    Jones TE; Morris RG; Horowitz JD
    Br J Clin Pharmacol; 2004 Mar; 57(3):263-9. PubMed ID: 14998422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease.
    Killalea SM; Krum H
    Am J Cardiovasc Drugs; 2001; 1(3):193-204. PubMed ID: 14728034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope.
    Phan TT; Shivu GN; Choudhury A; Abozguia K; Davies C; Naidoo U; Ahmed I; Yousef Z; Horowitz J; Frenneaux M
    Eur J Heart Fail; 2009 Sep; 11(9):881-6. PubMed ID: 19656806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs that Affect Cardiac Metabolism: Focus on Perhexiline.
    Chong CR; Sallustio B; Horowitz JD
    Cardiovasc Drugs Ther; 2016 Aug; 30(4):399-405. PubMed ID: 27106834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
    Inglis SC; Herbert MK; Davies BJ; Coller JK; James HM; Horowitz JD; Morris RG; Milne RW; Somogyi AA; Sallustio BC
    Pharmacogenet Genomics; 2007 May; 17(5):305-12. PubMed ID: 17429312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of interlaboratory performance in the provision of perhexiline therapeutic drug monitoring services in Australia.
    Sallustio BC; Morris RG
    Ther Drug Monit; 1999 Aug; 21(4):389-94. PubMed ID: 10442691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.